Aileron collaborates study in Nature: Stapled peptides...
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E.... More »
Genetic Engineering News - Nov. 11, 2009
Researchers 'notch' a victory toward new kind of cancer drug
Scientists have devised an innovative way to disarm a key protein considered to be 'undruggable,' meaning that all previous efforts to develop a drug against it have failed.... More »
Genetic Engineering News - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E.... More »
Genetic Engineering News - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
CAMBRIDGE, Mass. (Business Wire) -- Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today... More »
Globe Investor - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
CAMBRIDGE, Mass. - (Business Wire) Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today... More »
Earthtimes.org - Nov. 11, 2009
Aileron’s New Class of Drugs Shown to Get Inside Cells to...
Biotech , cancer , Drugs Luke Timmerman wrote: Cambridge, MA-based Aileron Therapeutics has bet the company on the idea that it has discovered a whole new class of drugs... More »
Xconomy - Nov. 11, 2009
Aileron collaborates study in Nature: Stapled peptides...
-- Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, , MD of... More »
Science Blog - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
- New Data Substantiates Potential for Stapled Peptides as Therapeutics for Key Intracellular Targets Not Addressable by Current Drug Modalities - - Aileron Developing... More »
Reuters - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
BusinessWire - --- Aileron Developing Stapled Peptides that Target Transcription Factors Across Multiple Diseases - Aileron Therapeutics, a biopharmaceutical company leading... More »
Forbes.com - Nov. 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research...
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E.... More »
PR inside - Nov. 11, 2009